Go Pro

Stephanie Davis Analyst Performance

Analyst at Barclays

Stephanie Davis is a stock analyst at Barclays focused in the healthcare sector, covering 12 publicly traded companies. Over the past year, Stephanie Davis has issued 4 stock ratings, including buy and hold recommendations. While full access to Stephanie Davis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Stephanie Davis' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
33 Last 11 Years
Buy Recommendations
78.79% 26 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy78.8%26 ratings
Hold21.2%7 ratings
Sell0.0%0 ratings

Out of 33 total stock ratings issued by Stephanie Davis at Barclays, the majority (78.8%) have been Buy recommendations, followed by 21.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
50.0% of companies on NASDAQ
6 companies
NYSE
41.7% of companies on NYSE
5 companies
OTCMKTS
8.3% of companies on OTCMKTS
1 company

Stephanie Davis, an analyst at Barclays, currently covers 12 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
10 companies
83.3%
Miscellaneous
1 company
8.3%
Industrials
1 company
8.3%

Stephanie Davis of Barclays specializes in stock coverage within the Healthcare sector, with additional focus on and Industrials companies.

Coverage Industries

IndustryPercentage
HEALTHCARE TECHNOLOGY
7 companies
58.3%
HEALTHCARE PROVIDERS & SERVICES
3 companies
25.0%
Miscellaneous
1 company
8.3%
PROFESSIONAL SERVICES
1 company
8.3%

Stephanie Davis' Ratings History at Barclays

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2/11/2026Boost Price Target$204.01$225.00Overweight
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
1/30/2026Upgrade$182.31$210.00Overweight
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
10/22/2025Boost Price Target$181.81$195.00Equal Weight
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
10/2/2025Boost Price Target$182.04$190.00Equal Weight
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4/23/2025Boost Price Target$172.56$185.00Equal Weight
Waystar Holding Corp. stock logo
WAY
Waystar
4/14/2025Lower Price Target$36.58$45.00Overweight
Waystar Holding Corp. stock logo
WAY
Waystar
2/19/2025Boost Price Target$45.11$50.00Overweight
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
1/31/2025Boost Price Target$163.97$175.00Equal Weight